Use of national guidelines for the introduction of Drotrecogin alfa (activated)

被引：0
|
作者：
S Mackenzie
L Patterson
L Plenderleith
F MacKirdy
机构：
[1] Scottish Intensive Care Society Audit Group,
[2] Western Infirmary,undefined
来源：
Critical Care | / 8卷 / Suppl 1期
关键词：
Systemic Inflammatory Response Syndrome; Drotrecogin Alfa; Systemic Inflammatory Response Syndrome Criterion; Prospective Audit; Apache Score;
D O I：
10.1186/cc2588
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
    R Vedantham
    B Iyowu
    [J]. Critical Care, 11 (Suppl 2):
  • [2] Strategies to optimize drotrecogin alfa (activated) use: Guidelines and therapeutic controversies
    Cohen, H
    Welage, LS
    [J]. PHARMACOTHERAPY, 2002, 22 (12): : 223S - 235S
  • [3] Introduction: severe sepsis and drotrecogin alfa (activated)
    Artigas, Antonio
    Martin, Claude D.
    [J]. CRITICAL CARE, 2007, 11 (Suppl 5)
  • [4] Introduction: severe sepsis and drotrecogin alfa (activated)
    Antonio Artigas
    Claude D Martin
    [J]. Critical Care, 11
  • [5] Drotrecogin alfa (activated) in the management of sepsis - Introduction
    Boucher, BA
    Olsen, KM
    [J]. PHARMACOTHERAPY, 2002, 22 (12): : 167S - 168S
  • [6] Patient selection guidelines and DUE for drotrecogin alfa (activated)
    Applebaum, S
    Carter, C
    Chuen, T
    Dedrick, S
    Dunsworth, G
    Edwards, W
    Fish, D
    Hodgman, T
    Huntress, J
    Jacobi, J
    Koerner, P
    Kornfuhrer, H
    Kuhl, D
    Mann, H
    Martin, S
    Mosko, P
    Rihn, T
    Rudis, M
    Shane, R
    Vanscoy, G
    [J]. FORMULARY, 2002, 37 : 3 - 15
  • [7] Drotrecogin alfa (activated)
    Lyseng-Williamson K.A.
    Perry C.M.
    [J]. Drugs, 2002, 62 (4) : 617 - 630
  • [8] Drotrecogin alfa (activated)
    Angus, DC
    [J]. DRUGS, 2002, 62 (04) : 631 - 632
  • [9] The results of the national program of drotrecogin alfa (activated) use in patients with severe sepsis in Poland
    Kubler, A
    Durek, G
    Mayzner-Zawadzka, E
    Majak, P
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (12) : A150 - A150
  • [10] Current issues regarding the use of drotrecogin alfa (activated)
    Hassan, E
    Mann, HJ
    [J]. PHARMACOTHERAPY, 2002, 22 (12): : 206S - 215S
12345